IGALMI PDUFA for Bipolar Disorders: Biotech Catalysts Oct 12, 2026

This week, we're keeping a close eye on several biotech catalysts, especially IGALMI's PDUFA date set for November 14, 2026. This decision could greatly influence BioXcel Therapeutics (BTAI) and its treatment for agitation linked to bipolar disorders and schizophrenia. Approval might establish IGALMI as a first-in-class therapy, offering a crucial alternative to current treatments.

The full biotech catalysts to watch

IGALMI's PDUFA Date: A Critical Decision

The PDUFA date for IGALMI (BTAI) is approaching on November 14, 2026. This decision is crucial for the acute treatment of agitation in patients with bipolar disorders and schizophrenia. IGALMI, a selective α2A-adrenergic receptor agonist, first received approval in April 2022. Its formulation as an orally dissolving sublingual film positions it as a first-in-class option, addressing a significant unmet need in managing acute agitation. Current treatments like benzodiazepines and intramuscular antipsychotics often require invasive administration and have notable side effects. With a probability of approval (PoA) at 10%, the stakes are high for BioXcel. While IGALMI has shown effectiveness for its approved use, the upcoming supplemental NDA for Alzheimer's disease agitation remains unclear. The PoA for this new indication is uncertain due to limited data on the specific submission under review.

PDS0301's Phase 2 Trial: Promising Early Signals

PDS Biotech's PDS0301 is another catalyst worth watching, with a Phase 2 trial set to report data on October 15, 2026. This treatment targets advanced liver-associated cancers, especially metastatic colorectal cancer (mCRC) in patients with unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases. PDS0301 uses a unique mechanism, binding necrotic DNA within tumors to deliver IL-12 to the tumor microenvironment. The trial has reported a 71.4% objective response rate at six months and an 80% overall survival rate at 24 months. While these figures suggest promising efficacy, the lack of randomization and reliance on interim analyses raise concerns about the robustness of these results. The PoA for PDS0301 stands at 18%, reflecting both the promising early signals and the historical challenges with IL-12 therapies. The upcoming data release will be crucial for the asset's future.

ART26.12's Phase 1 Study: Safety First

Artelo Biosciences is preparing for a Phase 1 study readout of its lead candidate ART26.12 on November 10, 2026. This FABP5 inhibitor is positioned as a novel non-opioid analgesic for neuropathic pain, although the current study involves healthy volunteers. The main focus is safety, assessing tolerability and pharmacokinetics. Initial results suggest ART26.12 is generally well tolerated, with no serious adverse events reported. However, the absence of efficacy data leaves the program's future uncertain, especially as it moves into patient studies. The PoA is estimated at 16%, slightly above the early-stage average. Investors should watch this trial's outcomes, as successful safety data could lead to further development in pain management.

SIL204's Phase 2/3 Study: The KRAS Targeting Approach

Silexion Therapeutics' SIL204 is on our radar with a Phase 2/3 study planned to report data on December 31, 2026. This second-generation siRNA program aims to silence KRAS in locally advanced pancreatic cancer. Despite the substantial market potential, valued at about $2.5 billion, the current treatment landscape remains challenging, with limited durable responses from existing therapies. SIL204's unique delivery mechanism via ultrasound-guided EUS endoscopy sets it apart from standard chemotherapy approaches. The study includes a small safety run-in followed by randomized segments, though no human efficacy data has yet been reported. The PoA for SIL204 is assessed at 18%. While the KRAS targeting mechanism is compelling, the program's future relies on demonstrating meaningful clinical benefits compared to traditional treatments.

Upcoming Catalysts: A Broader Look

Beyond the highlighted catalysts, several upcoming biotech catalysts merit attention. For instance, Labat's Nu-3 is set for review on October 22, 2026, focusing on infected diabetic foot ulcers. ADCT's ZYNLONTA has multiple readouts scheduled for December 31, 2026, including combination therapies for diffuse large B-cell lymphoma (DLBCL). These events underscore the dynamic landscape of biotech development, where multiple programs are vying for regulatory approval. Investors should monitor these catalysts as they could significantly influence market dynamics and stock valuations.

The bottom line

We'll closely monitor developments as these critical dates approach, providing updates on how these catalysts unfold.